The known role of EMT in the development of therapeutic resistance [5] provides another dimension to TRPV4 inhibition for the treatment of some breast cancers, the feasibility of which is demonstrated by the clinical trials of TRPV4 inhibitors for heart failure [29]. This evidence concerns the gene TRPV4 and heart failure.